Cargando…

The VIP/VPAC1R Pathway Regulates Energy and Glucose Homeostasis by Modulating GLP-1, Glucagon, Leptin and PYY Levels in Mice

SIMPLE SUMMARY: The current study is the first complete characterization of the phenotypic, metabolic, calorimetric, and homeostatic effects of VPAC1R in a null murine model. To evaluate the role of VPAC1R on body phenotype, feeding behavior, glucose/energy homeostasis, metabolic rate and plasma hor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sanford, Daniel, Luong, Leon, Vu, John P., Oh, Suwan, Gabalski, Arielle, Lewis, Michael, Pisegna, Joseph R., Germano, Patrizia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945135/ https://www.ncbi.nlm.nih.gov/pubmed/35336804 http://dx.doi.org/10.3390/biology11030431

Ejemplares similares

PACAP and VIP Neuropeptides’ and Receptors’ Effects on Appetite, Satiety and Metabolism
por: Vu, John P., et al.
Publicado: (2023)

Presence and dynamics of leptin, GLP-1, and PYY in human breast milk at early postpartum
por: Schueler, Jessica, et al.
Publicado: (2013)

Intermittent Hypoxia Up-Regulates Gene Expressions of Peptide YY (PYY), Glucagon-like Peptide-1 (GLP-1), and Neurotensin (NTS) in Enteroendocrine Cells
por: Shobatake, Ryogo, et al.
Publicado: (2019)

L‐Arginine Increases Postprandial Circulating GLP‐1 and PYY Levels in Humans
por: Amin, Anjali, et al.
Publicado: (2018)

Angiotensin II Type 1 Receptor-Dependent GLP-1 and PYY Secretion in Mice and Humans
por: Pais, Ramona, et al.
Publicado: (2016)

VIP/VPAC Axis Expression in Immune-Mediated Inflammatory Disorders: Associated miRNA Signatures
por: Lamana, Amalia, et al.
Publicado: (2022)

Glucagon, GLP-1 and Thermogenesis
por: González-García, Ismael, et al.
Publicado: (2019)

Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity
por: De Silva, Akila, et al.
Publicado: (2012)

The Effect of Exercise Intensity on Total PYY and GLP-1 in Healthy Females: A Pilot Study
por: Hallworth, Jillian R., et al.
Publicado: (2017)

The VIP-VPAC2 neuropeptidergic axis is a cellular pacemaking hub of the suprachiasmatic nucleus circadian circuit
por: Patton, Andrew P., et al.
Publicado: (2020)

The Cell-Autonomous Clock of VIP Receptor VPAC2 Cells Regulates Period and Coherence of Circadian Behavior
por: Hamnett, Ryan, et al.
Publicado: (2021)

Endogenous VIP VPAC(1) Receptor Activation Modulates Hippocampal Theta Burst Induced LTP: Transduction Pathways and GABAergic Mechanisms
por: Caulino-Rocha, Ana, et al.
Publicado: (2022)

The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and Expenditure in Obese Volunteers
por: Tan, Tricia, et al.
Publicado: (2017)

Glucagon-like peptide 1 (GLP-1)
por: Müller, T.D., et al.
Publicado: (2019)

Role of VPAC1 and VPAC2 receptors in the etiology of pregnancy rhinitis: an experimental study in rats
por: Ulkumen, Burak, et al.
Publicado: (2020)

A high carbohydrate, but not fat or protein meal attenuates postprandial ghrelin, PYY and GLP-1 responses in Chinese men
por: Parvaresh Rizi, Ehsan, et al.
Publicado: (2018)

CCK‐1 and CCK‐2 receptor agonism do not stimulate GLP‐1 and neurotensin secretion in the isolated perfused rat small intestine or GLP‐1 and PYY secretion in the rat colon
por: Modvig, Ida M., et al.
Publicado: (2020)

Seasonal changes in the expression of PACAP, VPAC1, VPAC2, PAC1 and testicular activity in the testis of the muskrat (Ondatra zibethicus)
por: Tang, Zeqi, et al.
Publicado: (2022)

PACAP regulates VPAC1 expression, inflammatory processes and lipid homeostasis in M1- and M2-macrophages
por: Witzel, Roman, et al.
Publicado: (2023)

On the relationship between glucose absorption and glucose‐stimulated secretion of GLP‐1, neurotensin, and PYY from different intestinal segments in the rat
por: Kuhre, Rune E., et al.
Publicado: (2017)

PAC(1), VPAC(1), and VPAC(2) Receptor Expression in Rat and Human Trigeminal Ganglia: Characterization of PACAP-Responsive Receptor Antibodies
por: Tasma, Zoe, et al.
Publicado: (2022)

Allosteric Modulation of the Activity of the Glucagon-like Peptide-1 (GLP-1) Metabolite GLP-1 9–36 Amide at the GLP-1 Receptor
por: Li, Naichang, et al.
Publicado: (2012)

Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor
por: Helmstädter, Johanna, et al.
Publicado: (2021)

The short chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents
por: Psichas, A, et al.
Publicado: (2015)

Serum levels of glucagon-like peptide (GLP)-1 and GLP-2 in patients with Hashimoto's thyroiditis
por: Jin, Yue, et al.
Publicado: (2015)

GLP-1/glucagon receptor co-agonism for treatment of obesity
por: Sánchez-Garrido, Miguel A., et al.
Publicado: (2017)

Appetite control and gastrointestinal hormonal behavior (CCK, GLP-1, PYY 1–36) following low doses of a whey protein-rich nutraceutic
por: Sukkar, Samir Giuseppe, et al.
Publicado: (2013)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

Effects of 2 Novel PYY(1-36) Analogues, (P(3)L(31)P(34))PYY(1-36) and PYY(1-36)(Lys(12)PAL), on Pancreatic Beta-Cell Function, Growth, and Survival
por: Lafferty, Ryan A, et al.
Publicado: (2019)

Failure of sucrose replacement with the non-nutritive sweetener erythritol to alter GLP-1 or PYY release or test meal size in lean or obese people
por: Overduin, Joost, et al.
Publicado: (2016)

No Evidence That Circulating GLP-1 or PYY Are Associated with Increased Satiety during Low Energy Diet-Induced Weight Loss: Modelling Biomarkers of Appetite
por: Lim, Jia Jiet, et al.
Publicado: (2023)

Expression of VPAC1 in a murine model of allergic asthma
por: Lauenstein, Hans D, et al.
Publicado: (2013)

The G Protein-Coupled Receptor, VPAC1, Mediates Vasoactive Intestinal Peptide-Dependent Functional Homeostasis of the Gut Microbiota
por: Ericsson, Aaron C., et al.
Publicado: (2022)

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
por: Saraiva, Francisco Kerr, et al.
Publicado: (2014)

Modulation of Cardiac Ventricular Excitability by GLP-1 (Glucagon-Like Peptide-1)
por: Ang, Richard, et al.
Publicado: (2018)

Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia
por: Ja’arah, Daria, et al.
Publicado: (2021)

Modulation of Prostanoids Profile and Counter-Regulation of SDF-1α/CXCR4 and VIP/VPAC2 Expression by Sitagliptin in Non-Diabetic Rat Model of Hepatic Ischemia-Reperfusion Injury
por: Krzystek-Korpacka, Małgorzata, et al.
Publicado: (2021)

The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice
por: Ørgaard, Anne, et al.
Publicado: (2017)

Plasma levels of glucagon but not GLP-1 are elevated in response to inflammation in humans
por: Modrzynska, Justyna, et al.
Publicado: (2021)

Zhuang-Gu-Fang Treats Osteoporosis in Ovariectomized Rats by Increasing the Osteogenesis-Related Factors Leptin, Ghrelin, and PYY
por: Chen, Yuanjin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pgjo0ufb1skr3gu2adlr9ek8di